entertainment -WSS

entertainment

author：leisure time 2025-09-28 21:06:47 - browse：9

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Key House Republican on health care plans exit from Congress

WSS

Gilead might be held responsible for not developing a drug

What should King Charles tell the public about his cancer?

For Medicare Advantage, Democrats want stronger protections around AI

Making the case for fair compensation in clinical trials

Gilead might be held responsible for not developing a drug

UnitedHealth argues against case alleging wrongful AI care denials

focus

entertainment

focus

Activists slam private health insurers over coverage restrictions

Study finds gene variants tied to breast cancer risk in Black women

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eyeing GLP

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What we’ve learned from the Aduhelm mess

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

H5N1 virus can be tracked in retail milk, scientists say

Alkermes shareholders re

As a primary care physician, here's how I hope to partner with AI

explore

H5N1 bird flu outbreak: Second human case reported, in Michigan

Senators start work on Medicare physician payment reform

BioAge raises $170M for combination therapy with Zepbound

ASCO eve: Let’s set the table for this year's meeting

Doctors' information doesn't help them choose wisely when sick

At flashy new research hub, AstraZeneca lays out ambitious growth goals

focus

explore

Wikipedia

Wikipedia